Introduction
Narcolepsy, cataplexy, narcolepsy, EDS, loss of hypothalamic hypocretin, NT2 [
NARCOLEPSY, NARCOLEPSY WITHOUT CATAPLEXY, CATAPLEXY, NARCOLEPSY, NARCOLEPSY TYPE 1, NARCOLEPSY WITH CATAPLEXY
Narcolepsy is classified into two subtypes: narcolepsy type 1 (NT1), or narcolepsy with cataplexy, and narcolepsy type 2 (NT2), known as narcolepsy without cataplexy [The etiology of NT1 is recognized to be due to severe loss of hypothalamic hypocretin (orexin) neurons resulting in low or undetectable cerebrospinal fluid (CSF) orexin levels [Guidelines in both the US and Europe recommend sodium oxybate (SXB, sodium salt of ɣ-hydroxybutyrate) for the treatment of adults with either NT1 or NT2 [The first once-at-bedtime oxybate (LUMRYZ, sodium oxybate for extended-release oral suspension [FT218; once-nightly sodium oxybate (ON-SXB)], Avadel Pharmaceuticals, Chesterfield, MO) was recently approved by the US Food & Drug Administration (FDA) for treatment of cataplexy or EDS in adults with narcolepsy [There are limited published data on treatment efficacy in people with NT2 [